ACST: התחייבויות שוטפות של החברה Acasti Pharma

Acasti Pharma (ACST) operations are independent of economic fluctuations, as demand for cardiology care remains stable. The business relies on royalty payments, utilizing outsourced production to minimize capital expenditures. The company is currently in the testing phase for new molecules, with resources allocated to clinical trials. This metric stands at 0.00. The chart of short-term liability costs is presented below.

By utilizing contract manufacturing organizations (CMO) in the US, Acasti Pharma (ACST) minimizes capital expenditures, which directly impacts its liability structure. By analyzing the evolution of short-term debt load relative to working capital, an investor can assess the balance between reducing default risk and a potential slowdown in expansion due to limited credit lines.